Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 8;15(6):886-888.
doi: 10.2215/CJN.09000819. Epub 2020 Feb 4.

Screening for Cancer in Patients with Glomerular Diseases

Emmanuelle Plaisier  1   2   3   4   5 , Pierre Ronco  1   2   3   4   5
Affiliations

Screening for Cancer in Patients with Glomerular Diseases

Emmanuelle Plaisier et al. Clin J Am Soc Nephrol. .
No abstract available

Keywords: Cancer; cost-benefit analysis; cytosolic phospholipases A2; early detection of cancer; follow-up studies; human PLA2R1 protein; humans; immunosuppressive agents; kidney; membranoproliferative glomerulonephritis; membranous nephropathy; neoplasms; nephrologists; nephrology; nephrotic syndrome; phospholipase A2 receptors; phospholipases A2; recurrence; risk factors; thrombospondins; treatment failure.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Routine and targeted cancer screening in patients with glomerulopathy. The algorithm shows the main types of tumor associated with the various types of glomerulopathy and the two-step work-up including routine screening (all patients), followed by targeted screening (depending on the patient’s cancer risk factors). In thrombospondin type-1 domain-containing protein 7A (THSD7A)-positive patients with membranous nephropathy and in those that are double negative, we suggest search for an occult malignancy if the routine and targeted screening is negative. GI, gastrointestinal; PAP test, Papanicolaou test; PLA2R, phospholipase A2 receptor; PSA, prostatic-specific antigen.
See this image and copyright information in PMC

References

    1. Bjørneklett R, Vikse BE, Svarstad E, Aasarød K, Bostad L, Langmark F, Iversen BM: Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 50: 396–403, 2007 - PubMed
    1. Cambier JF, Ronco P: Onco-nephrology: Glomerular diseases with cancer. Clin J Am Soc Nephrol 7: 1701–1712, 2012 - PubMed
    1. Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J; GN-PROGRESS Study Group : Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 70: 1510–1517, 2006 - PubMed
    1. De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC: A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol 28: 421–430, 2017 - PMC - PubMed
    1. Zaghrini C, Seitz-Polski B, Justino J, Dolla G, Payré C, Jourde-Chiche N, Van de Logt AE, Booth C, Rigby E, Lonnbro-Widgren J, Nystrom J, Mariat C, Cui Z, Wetzels JFM, Ghiggeri G, Beck LH Jr., Ronco P, Debiec H, Lambeau G: Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int 95: 666–679, 2019 - PubMed

MeSH terms